Avacta shares climb after regulatory approval - could this continue?
Avacta Group has gone from strength to strength in the past year, using its expertise to develop highly accurate Covid-19 tests. Following regulatory approval for a new antigen test, will the Avacta share price rise again?
- The Avacta share price has risen 1400% since January 2020
- Shares rose to 220.5p when markets opened on 17 June
- Avacta was one of the first to produce rapid Covid-19 tests for the mass market
- UK regulatory authorities have just approved a new Avacta antigen test
- Ready to trade the Avacta share price? Open an account today
Why have Avacta shares risen by 1400%?
Outside a limited circle of health tech investors, few people had heard of Avacta Group this time 18 months ago. The Yorkshire-based life sciences company originally focused on cancer treatments and diagnostics but decided to pivot towards developing rapid Covid-19 tests not long after the pandemic hit.
Thanks to the high levels of accuracy from Avacta tests, which initially hovered at around 96%, the Avacta share price surged continuously throughout 2020 and beyond, landing at a peak of 275p on 10 May 2021.
Although the share price has dipped since then, it was bolstered once more on 7 June following the news that UK regulatory authorities had approved Avacta's rapid lateral flow antigen tests for general use. This means that the tests will likely be used widely throughout the UK by both public and private bodies.
Only four days later, on 11 June, Avacta experienced another win when those same antigen tests, which reportedly have a 100% accuracy rate, were granted approval by the European Medicines Agency. The share price quickly jumped once it was clear that Avacta could begin selling its rapid tests for use throughout the EU bloc, which is home to 445 million people.
What are the risks ahead for the Avacta share price?
Although it would seem that Avacta is in a solid position and that its continued revenues are assured, there are significant dangers ahead for the company. Most alarming is the fact that Avacta is yet to make a profit from its Covid tests, having earned £3.64 million in revenue in 2020, while reporting losses of more than £18 million.
Meanwhile, Avacta's £650 million market cap is more than 140 times higher than the expected revenues for the whole of 2021, which are expected to reach £4.5 million. Although investors clearly remain optimistic about the future of the company, these underlying metrics could spell trouble for the future share price.
Is the Avacta share price on the rise for the long term? Trade Avacta shares today
Take your position on UK shares for just a small initial deposit with CFDs.
Open an account to start trading or investing in UK shares.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.
